

Crohn's Disease - Pipeline Insight, 2021

<https://marketpublishers.com/r/C6D01E6584B9EN.html>

Date: May 2021

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: C6D01E6584B9EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Crohn's Disease - Pipeline Insight, 2021," report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Crohn's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Crohn's Disease Understanding

Crohn's Disease: Overview

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn's disease has the potential to progress extensively.

The disease can be witnessed in any age group; however, it is seen to be developing mostly in between 20 and 30 years of age. About one-sixth of patients present before the age of 15 and often with severe disease. The exact pathogenesis of CD is unknown, although there are a number of genetic and environmental factors that have been shown to increase the risk of the disease and lead to the aberrant gut immune response

characteristic of the disease.

Crohn's is a chronic illness that requires expensive medications, often hospitalization and/or surgery, and results in a heavy social and economic toll. Based on its phenotypic progression, Crohn's can be characterized as inflammatory, fibrostenotic, or fistulizing, and may progress to extraintestinal or systemic manifestations. The broad clinical spectrum of the disease portends a diagnostic challenge, and requires a multi-disciplinary approach to provide the appropriate management. Various treatments and therapies are available that help in order to ease away the symptoms related to Crohn's disease. Treatment of Crohn's disease is guided by severity, behavior, and disease location, along with anatomic site, appearance of complications, treatment refractoriness and dependency to steroids.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Crohn's Disease R&D. The therapies under development are focused on novel approaches for Crohn's Disease.

Crohn's Disease Emerging Drugs Chapters

This segment of the Crohn's Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Crohn's Disease Emerging Drugs

Filgotinib: Gilead Sciences

Filgotinib is an orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation

and activation of certain immune cells.

In December 2020 Gilead and Galapagos announced new commercialization and development agreement for Jyseleca (Filgotinib). The announcement followed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA. It is currently in Phase III stage of development for Crohn's Disease.

Risankizumab: Abbvie

Risankizumab is a humanized, monoclonal IgG1 class antibody whose action is based on binding to the p19 subunit of IL-23. After binding to the antibody, IL-23 is selectively blocked, thus inhibiting its pro-inflammatory activity. Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, atopic dermatitis psoriatic arthritis and Hidradenitis Suppurativa. It is currently in Phase III stage of development for Crohn's Disease.

In November 2016, Abbvie receives Orphan Drug Designation for investigational IL-23 inhibitor risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with crohn's disease.

Further product details are provided in the repor

Crohn's Disease: Therapeutic Assessment

This segment of the report provides insights about the different Crohn's Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Crohn's Disease

There are approx. 80+ key companies which are developing the Crohn's Disease. The companies which have their Crohn's Disease drug candidates in the most advanced stage, i.e. Phase III include, Gilead Sciences.

Phases

DelveInsight's report covers around 90+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Crohn's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Crohn's Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Crohn's Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Crohn's Disease drugs.

Crohn's Disease Report Insights

Crohn's Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Crohn's Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Crohn's Disease drugs?

How many Crohn's Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Crohn's Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Crohn's Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Crohn's Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Gilead Sciences

Abbvie

Eli Lilly and Company

Celgene

AstraZeneca

Mesoblast

Alfasigma

Tiziana Life Sciences

Pfizer

Dermavant Sciences GmbH

Cytocom

Amgen

Priothera

SLA Pharma

HAV Vaccines Ltd

Enzo Biochem

VHsquared Ltd.

Stero Biotechs

Reystone Biopharma Company Limited

Qu Biologics

Provention Bio

Mitsubishi Tanabe Pharma Corporation

Takeda Pharmaceuticals

Soligenix

Immunic

Atlantic Healthcare

4D Pharma

Landos Biopharma

Janssen

Protagonist Therapeutics

Roche

Eisai

Bristol-Myers Squibb

Iltoo Pharma

Fast Forward Pharmaceuticals

Suzhou Connect Biopharmaceuticals

Theravance Biopharma

TaiwanJ Pharmaceuticals

Active Biotech

Celularity

Alpha Cancer Technologies

Koutif Therapeutics

Winston Pharmaceuticals

Tract Therapeutics

Trio medicines

Tetherex Pharmaceuticals

ChemoCentryx

Algernon Pharmaceuticals

Neuclone

Key Products

Filgotinib

Risankizumab

Mirikizumab

Ozanimod

Brazikumab

Risankizumab

Upadacitinib

Remestemcel-L

Rifaximin

Foralumab

ABX464

Etrasimod

CYTO-201

Masitinib

Mocravimod

Ortem Topical metronidazole

HAV anti-MAP vaccine

Alequel

V565

Cannabidiol

SHR0302

QBECO-SSI

PRV-6527

PF-06651600

MT-1303

TAK-018

SGX203

IMU 838

Brepocitinib

Alicaforsen

Bacteroides thetaiotaomicron

BT-11

JNJ-64304500

PTG-200

RG-7880

E6011

BMS-986165

Spesolimab

Aldesleukin

FFP104

CBP-307

TD-1473

JKB-122

Laquinimod

PDA-001

IMU-856

ACT-101

KT-1002

Civamide

TregCel

TR8

SelK2

CCX507

NP-178

NeuLara

Contents

- Introduction
- Executive Summary
- Crohn's Disease: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Crohn's Disease– DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Crohn's Disease companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- Crohn's Disease Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Risankizumab: AbbVie
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Omilancor: Landos Biopharma
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis

TregCel: Tract Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

OTL104: Orchard Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Crohn's Disease Key Companies

Crohn's Disease Key Products

Crohn's Disease- Unmet Needs

Crohn's Disease- Market Drivers and Barriers

Crohn's Disease- Future Perspectives and Conclusion

Crohn's Disease Analyst Views

Crohn's Disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Crohn's Disease
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Crohn's Disease
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Crohn's Disease - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C6D01E6584B9EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6D01E6584B9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970